December 2019

OPHTHALMOLOGY

UPDATES IN CARE FOR DIABETIC RETINOPATHY

Featuring: Lee M. Jampol, MD

Episode Summary

 Diabetic macular edema (DME), an accumulation of fluid in the retina from leaking blood vessels, is a major cause of visual acuity loss worldwide. Anti-vascular endothelial growth factor (VEGF) injections are a standard treatment today. VEGF is a protein that stimulates leakage from blood vessels, so blocking the protein can help reduce edema, or swelling of the retina.

Joining the Better Edge podcast is Lee M. Jampol, MD, who co-authored a study published in JAMA, which found that waiting to start injection treatments until patients began to experience vision loss had similar outcomes when compared to starting injection treatments as soon as the condition was diagnosed. The injections are time consuming, costly and can carry the risk of harmful side effects, so waiting until the treatment is necessary has advantages for both the patient and providers. 
Lee M. Jampol, MD, a Louis Feinberg, MD, Professor of Ophthalmology. 

Refer a Patient

Northwestern Medicine welcomes the opportunity to partner with you in caring for your patients. ​

You May Also Like